Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: isotretinoin Clear all

Conditions: Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions: Aldesleukin, Dinutuximab, Isotretinoin, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Sargramostim; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 1,449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2025
U.S. locations: 172
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 129 more

Conditions: CYP2D6 Polymorphism
Interventions: Isotretinoin, dextromethorphan; Drug
Lead sponsor: University of Washington; Other
Eligibility: 12 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Proliferative Vitreoretinopathy
Interventions: Isotretinoin; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 80 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Recurrent Neuroblastoma, Refractory Neuroblastoma
Interventions: Dinutuximab, Isotretinoin, Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 14
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more

Conditions: Melanoma (Skin), Non-melanomatous Skin Cancer
Interventions: isotretinoin; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: High Risk Neuroblastoma
Interventions: Aldesleukin, Diagnostic Laboratory Biomarker Analysis, Dinutuximab, Isotretinoin, Sargramostim; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 32
States / cities: Loma Linda, California • Los Angeles, California • Orange, California + 25 more

Conditions: HIV Infections, Anus Neoplasms
Interventions: Isotretinoin, Interferon alfa-2a; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions: Isotretinoin, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more

Conditions: Neuroblastoma
Interventions: Ceritinib, dasatinib, sorafenib, vorinostat, DFMO; Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: Up to 22 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2035
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more

Conditions: Oligospermia, Azoospermia, Nonobstructive, Infertility
Interventions: isotretinoin, Human chorionic gonadotrophin (hCG); Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 50 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Glioblastoma Multiforme, Anaplastic Glioma
Interventions: Vorinostat, Isotretinoin, Surgical Resection, Temozolomide; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuroblastoma
Interventions: Hu3F8, GM-CSF, Isotretinoin; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Kidney Cancer
Interventions: aldesleukin, recombinant interferon alfa, fluorouracil, isotretinoin, surgical procedure; Biological · Drug · Procedure
Lead sponsor: University of New Mexico; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2002
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Glioblastoma, Gliomas
Interventions: Temozolomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 3
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 365 Days to 30 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 152
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more

Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate; Radiation · Procedure · Drug + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more

Conditions: Neuroblastoma
Interventions: anti-GD2 murine IgG3 monoclonal antibody 3F8; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: recombinant interferon alfa, estramustine phosphate sodium, isotretinoin, mitoxantrone hydrochloride, paclitaxel, vinorelbine ditartrate; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 19
States / cities: Denver, Colorado • Atlanta, Georgia • Decatur, Georgia + 16 more

Conditions: Brain Tumors
Interventions: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 6 Months to 21 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 16
States / cities: Phoenix, Arizona • Atlanta, Georgia • Lihue, Hawaii + 13 more

Conditions: Lymphoma, T-Cell, Mycosis Fungoides, Hematologic Neoplasms
Interventions: Isotretinoin (Accutane), Interferon Alpha; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acne Vulgaris
Interventions: Isotretinoin, Tetracycline; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 12 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Male Infertility, Klinefelter's Syndrome, Y-chromosome Microdeletions
Interventions: 13-cis retinoic acid, Calcitriol; Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 60 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Neuroblastoma
Interventions: Isotretinoin; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 30 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Primary Refractory Neuroblastoma
Interventions: MAb-3F8, Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), 13-cis-Retinoic Acid; Biological
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Months to 13 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 15
States / cities: Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 12 more

Search by objective public record fields.

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Effects of Isotretinoin on CYP2D6 Activity

Isotretinoin for Proliferative Vitreoretinopathy

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

Isotretinoin in Preventing Skin Cancer

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.

Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm

Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

Weekly Isotretinoin vs Tetracycline for Moderate Acne

RA-2 13-cis Retinoic Acid (Isotretinoin)

Aflac ST1001 Prolonged Isotretinoin

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients